Eric Benevich insider trades

Open-market stock purchases and sales by Eric Benevich, Chief Commercial Officer at Neurocrine Biosciences Inc, from SEC Form 4 filings since Jun 1, 2015.

Recent trades

DateStockTradeValue
Sep 11, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Sep 11, 2026NBIX Neurocrine Biosciences IncSold (not open market)$529K
Sep 9, 2026NBIX Neurocrine Biosciences IncSold$333K
Sep 9, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
May 11, 2026ATYR aTYR PHARMA IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$131K
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$140K
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$1.1M
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 12, 2026NBIX Neurocrine Biosciences IncSold (not open market)$133K
Feb 12, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Jan 31, 2026NBIX Neurocrine Biosciences IncSold (not open market)$176K
Jan 31, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Nov 28, 2025NBIX Neurocrine Biosciences IncBought (not open market)—
Nov 28, 2025NBIX Neurocrine Biosciences IncSold$906K
Nov 28, 2025NBIX Neurocrine Biosciences IncBought (not open market)—

Companies traded

  • NBIX Neurocrine Biosciences Inc: 61 sales, last Sep 11, 2026
  • ATYR aTYR PHARMA Inc: other filings, last May 11, 2026

Get free alerts when Eric Benevich files a new trade →